Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Download Full Press Release

PDF Download

 

Convatec Group Plc and its subsidiaries ("Convatec" or the "Group"), a leading global medical products and technologies company focused on therapies for the management of chronic conditions, today reports audited Annual Results for the twelve months ended 31 December 2018 in line with the revised guidance provided in October 2018.

FY2018 key points:

  • Group reported revenue of $1,832.1 million grew 3.8% year on year, 2.7%2 CER or 0.2%3 organically;
  • Reported EBIT5 of $267.7 million, grew 8.0% year on year due to lower restructuring and pre-IPO share-based payments;
  • Adjusted1 EBIT5 of $429.4 million was down 6.0% year on year primarily due to increased levels of investment in commercial activities and negative mix, more than offsetting increased revenue; adjusted1 EBIT margin 23.4% (2017: 25.9%);

Actions to address strategy execution issues:

  • Transformation Initiative established to implement a refreshed execution model “Pivot to Growth” to deliver strategy more effectively and drive higher revenue growth and profitability;
    • Investment: total of around $150 million over three years, with a two to three year payback expected. Around 30% of this total will be capex investment, with the remaining 70% being operational spend related to restructuring, project management and other transformation costs which will cease at the end of the three year period;
    • By year three of the Transformation Initiative we also expect to incur $50 million of ongoing annual costs related to commercial spend and R&D, building from $15 million in 2019;
    • Benefits: higher revenue growth, $80 million gross annual cost savings by year three, (increasing to $120 million gross annual savings by 2023), and improved profit margin;

Guidance:  

  • Guidance for FY2019: organic revenue growth expected to be 1% to 2.5%, adjusted EBIT margin 18% to 20%, including $50 million of operational spend associated with the Transformation Initiative and costs related to MDR (Medical Device Regulation). Excluding these transformation costs and MDR, the adjusted EBIT margin would be 21% to 22.5%;
  • Medium to long term4, targeting revenue growth in line with or above market and adjusted EBIT margin expansion.

 

Rick Anderson, Group Chief Executive Officer, commented

“These are disappointing results, in light of our revenue and margin guidance at the beginning of 2018. With the Executive Committee, I have undertaken an extensive review of the business since my appointment as CEO and it is clear that swift and strong action is required to address the failures in execution which have caused the Company to underperform.

“Following Board approval, we are now implementing a refreshed execution model to support our strategy and deliver sustainable and profitable growth. We will achieve this by concentrating on those product and market segments which offer the best returns, developing a strong and innovative pipeline of new products, simplifying our business to run it more efficiently and investing to strengthen our commercial and operational execution. This model can be leveraged by an incoming CEO, without constraining any potential strategic changes they may wish to implement.

“We have solid fundamentals, robust cash flows and we have reduced our leverage, but need to invest in the business over the next three years. I fully believe the changes we are making to our execution model will deliver the returns that our shareholders and other stakeholders rightly expect in the future.

“The search for a permanent CEO has made significant progress since October, with a very strong short-list of candidates. The Board is moving quickly on this key appointment.”

(...)

Download the full text of this announcement and the presentation for the Analysts and Investors meeting

 

Enquiries

 
Analysts and Investors 
                                                                                                                     

investorrelations@convatec.com

John Crosse, VP Investor Relations

+44 (0)7500 141435

Kirsty Law, Director Investor Relations     

Mark Reynolds, Director Investor Relations

+44 (0)7470 909582

+44 (0)7551 036625


Media


mediarelations@convatec.com

Bobby Leach, VP Group Corporate Affairs                      

+44 (0)7770 842226

Finsbury

+44 (0)207 2513801

 

Press Release

See all

5/13/2022

5/13/2022

Convatec Group Plc Annual Results 2018

Convatec Group Plc Annual Results 2018

Read more

5/13/2022

5/13/2022

2018 Annual Report & Accounts

2018 Annual Report & Accounts

Read more

5/13/2022

5/13/2022

Appointment of Chief Executive Officer

Appointment of Chief Executive Officer

Read more

5/13/2022

5/13/2022

Board Changes

Board Changes

Read more

5/13/2022

5/13/2022

Results of Annual General Meeting

Results of Annual General Meeting

Read more

5/13/2022

5/13/2022

Convatec partners with EWMA to support Research Grants in 2019

Convatec partners with EWMA to support Research Grants in 2019

Read more

5/13/2022

5/13/2022

Board Change

Board Change

Read more

5/13/2022

5/13/2022

Beta Bionics and Convatec announce partnership to bring Unomedical infusion set portfolio to the iLet™ Bionic Pancreas System

Beta Bionics and Convatec announce partnership to bring Unomedical infusion set portfolio to the iLet™ Bionic Pancreas System

Read more

5/13/2022

5/13/2022

Convatec Group Plc First Half Results 2019

Convatec Group Plc First Half Results 2019

Read more

5/13/2022

5/13/2022

John McAdam appointed Chairman of Convatec

John McAdam appointed Chairman of Convatec

Read more

5/13/2022

5/13/2022

Acquisition of Southlake Medical Supplies

Acquisition of Southlake Medical Supplies

Read more

5/13/2022

5/13/2022

Trading Update for the three months ended 30 September 2019

Trading Update for the three months ended 30 September 2019

Read more